0000000001111558

AUTHOR

Odile Launay

showing 12 related works from this author

Long-term Immune Response to Hepatitis B Virus Vaccination Regimens in Adults With Human Immunodeficiency Virus 1: Secondary Analysis of a Randomized…

2016

International audience; IMPORTANCE:Data on long-term immune responses to hepatitis B virus (HBV) vaccination in adults with human immunodeficiency virus 1 (HIV-1) infection are scarce.OBJECTIVE:To compare long-term (up to month 42) immune responses to the standard HBV vaccination regimen with a 4-injection intramuscular double-dose regimen and a 4-injection intradermal low-dose regimen.DESIGN, SETTING, AND PARTICIPANTS:The phase 3, open-label, multicenter parallel-group (1:1:1 allocation ratio) randomized clinical trial was conducted from June 28, 2007, to October 23, 2008, at 33 centers in France. Participants included 437 HBV-seronegative adults with HIV-1 and CD4 cell counts of more than…

0301 basic medicineMaleHIV Infectionsmedicine.disease_causelaw.inventionMESH: HIV-10302 clinical medicineRandomized controlled triallawSingle-Blind Method030212 general & internal medicineMESH: Hepatitis B AntibodiesMESH: Treatment Outcomeeducation.field_of_study[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyMESH: Middle AgedVaccinationMESH: Follow-Up StudiesMESH: HIV InfectionsHepatitis BMiddle Aged16. Peace & justiceHepatitis BMESH: Injections Intramuscular3. Good healthVaccinationTreatment OutcomeFemaleFranceIntramuscular injectionAdultmedicine.medical_specialtyHepatitis B vaccineInjections Intradermal030106 microbiologyPopulationInjections Intramuscular03 medical and health sciencesInternal medicineInternal MedicinemedicineHumansHepatitis B VaccinesHepatitis B AntibodieseducationHepatitis B virusMESH: Injections IntradermalMESH: Hepatitis B VaccinesMESH: HumansMESH: Hepatitis Bbusiness.industryMESH: AdultMESH: Vaccinationmedicine.diseaseMESH: Single-Blind MethodMESH: MaleSurgeryMESH: FranceRegimenHIV-1MESH: BiomarkersbusinessMESH: FemaleBiomarkers[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct

Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a mu…

2015

Equipe CHU UB (EA) Pôle MERS CT3 Hors Enjeu ANRS HB04 B-BOOST study group : Hugues Aumaitre (Centre Hospitalier Marechal Joff re, Perpignan, France); Jean-Luc Berger (Centre Hospitalier Universitaire de Reims– Hopital Robert Debre, Reims, France); Alain Devidas (Hopital Gilles de Corbeil–Centre Hospitalier Sud Francilien, Corbeil Essonne, France); Sophie Abgrall (Centre Hospitalier Universitaire Avicenne, Avicenne, France); Olivier Patey (Centre Hospitalier Intercommunal de Villeneuve St Georges, Villeneuve Saint Georges, France); Marie-Christine Drobacheff Thiebaut (Centre Hospitalier Universitaire de Besancon–Hopital Saint Jacques, Besancon, France); Frederic Lucht (Centre Hospitalier Uni…

MalePediatricsefficacyHIV InfectionsBooster doselaw.invention0302 clinical medicineRandomized controlled triallaw[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesvaccineSingle-Blind Method030212 general & internal medicineVaccines Synthetic0303 health sciencesnumberinfected patientMiddle AgedHepatitis BHepatitis B3. Good healthVaccinationTreatment OutcomeInfectious Diseaseshomosexual man[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesFemaleFranceViral hepatitisAdultmedicine.medical_specialtyHepatitis B vaccineImmunization SecondaryvirusYoung Adult03 medical and health sciencesmedicineHumansHepatitis B VaccinesHepatitis B AntibodiesAgedIntention-to-treat analysis030306 microbiologybusiness.industrymedicine.diseaserateRegimeninjection[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessimpaired response
researchProduct

Vaccination Against Hepatitis B Virus (HBV) in HIV-1-Infected Patients With Isolated Anti-HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Stu…

2016

International audience;  Although an isolated anti-hepatitis B virus (HBV) core antibody (anti-HBc) serological profile is frequent in human immunodeficiency virus (HIV)-infected patients, data on HBV vaccination in these patients are scarce.  A prospective multicenter study was conducted to assess the immunogenicity of HBV vaccination in 54 patients with an isolated anti-HBc profile and undetectable HIV load. They were vaccinated with 1 dose (20 µg) of recombinant HBV vaccine. Those with an anti-HBV surface antibody (anti-HBs) level of 100 mIU/mL 4 weeks after a single recall dose of HBV vaccine should be further vaccinated with a reinforced triple double-dose scheme.

AdultMaleHuman immunodeficiency virus (HIV)HIV Infectionsmedicine.disease_causeVirusSerology03 medical and health sciences0302 clinical medicineImmunogenicity Vaccine[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyAntiretroviral Therapy Highly ActiveHepatitis B virus HBVImmunology and AllergyMedicineHumansHepatitis B Vaccines030212 general & internal medicineProspective StudiesHepatitis B AntibodiesProspective cohort study[SDV.MP] Life Sciences [q-bio]/Microbiology and ParasitologyVaccines Syntheticbiologybusiness.industryImmunogenicityvirus diseasesMiddle AgedHepatitis BVirologyHepatitis B Core Antigensdigestive system diseasesVaccinationInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyImmunologybiology.proteinHIV-1030211 gastroenterology & hepatologyFemaleAntibodybusiness
researchProduct

Patients With Isolated Hepatitis B Core Antibody: Has the Time Come to Vaccinate?

2017

International audience

Microbiology (medical)MESH: Antiviral AgentsMESH: Hepatitis B ChronicMEDLINEMESH: Hepatitis B Core AntigensAntiviral Agents03 medical and health sciences0302 clinical medicineHepatitis B ChronicmedicineHumansHepatitis B Vaccines030212 general & internal medicineHepatitis B AntibodiesMESH: Hepatitis B AntibodiesMESH: Hepatitis B VaccinesMESH: Humansbusiness.industryHepatitis Bmedicine.diseaseVirologyHepatitis B Core AntigensHepatitis b core antibodyMESH: DNA ViralInfectious Diseases[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieImmunologyDNA Viral030211 gastroenterology & hepatology[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusiness
researchProduct

Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19

2023

Abstract Background We describe demographic features, treatments and clinical outcomes in the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) COVID-19 cohort, one of the world's largest international, standardized data sets concerning hospitalized patients. Methods The data set analysed includes COVID-19 patients hospitalized between January 2020 and January 2022 in 52 countries. We investigated how symptoms on admission, co-morbidities, risk factors and treatments varied by age, sex and other characteristics. We used Cox regression models to investigate associations between demographics, symptoms, co-morbidities and other factors with risk of death, admiss…

MaleEpidemiologyMESH: HospitalizationMESH: Proportional Hazards ModelsMESH: Risk FactorsRisk FactorsMESH: Childcohort studyMESH: COVID-19HumansMESH: SARS-CoV-2ChildProportional Hazards ModelsMESH: HumansMESH: Middle AgedSARS-CoV-2COVID-19risk of deathGeneral MedicineMiddle AgedCOVID-19; SARS-CoV-2; co-morbidities; cohort study; risk of death; symptoms; treatmentsMESH: MaleHospitalizationIntensive Care Unitsco-morbiditiestreatmentssymptomsMESH: Intensive Care Units[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieCOVID-19/therapy
researchProduct

The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults…

2016

Supplemental Digital Content is available in the text

0301 basic medicinemyalgiaAdultCD4-Positive T-LymphocytesMalemedicine.medical_specialty4850AdolescentMedizinHIV InfectionsVacunesPlaceboAntibodies Virallaw.invention03 medical and health sciencesYoung Adult0302 clinical medicineRandomized controlled triallawInternal medicineVIH (Virus)medicineHumansSingle-Blind Method030212 general & internal medicineYoung adultAdverse effectAIDS VaccinesVaccinesHIV (Viruses)business.industryClinical Trial/Experimental StudyGeneral MedicineConfidence intervalCD4 Lymphocyte CountClinical trial030104 developmental biologyAnti-Retroviral AgentsImmunologyAntibody FormationComputingMethodologies_DOCUMENTANDTEXTPROCESSINGHIV-1Femalemedicine.symptombusinessViral loadResearch Article
researchProduct

2011–12 Seasonal Influenza Vaccines Effectiveness against Confirmed A(H3N2) Influenza Hospitalisation: Pooled Analysis from a European Network of Hos…

2013

BackgroundInfluenza vaccination strategies aim at protecting high-risk population from severe outcomes. Estimating the effectiveness of seasonal vaccines against influenza related hospitalisation is important to guide these strategies. Large sample size is needed to have precise estimate of influenza vaccine effectiveness (IVE) against severe outcomes. We assessed the feasibility of measuring seasonal IVE against hospitalisation with laboratory confirmed influenza through a network of 21 hospitals in the European Union.MethodsWe conducted a multicentre study in France (seven hospitals), Italy (one hospital), and Navarra (four hospitals) and Valencia (nine hospitals) regions in Spain. All ≥1…

MaleViral DiseasesEpidemiologyPilot ProjectsLogistic regressionmedicine.disease_cause0302 clinical medicineInfluenza A virusClinical Epidemiology030212 general & internal medicineEpidemiological Methodsmedia_commonAged 80 and overeducation.field_of_studyVaccinesMultidisciplinaryQVaccinationREpidemiology of AgingMiddle Aged3. Good healthVaccinationHospitalizationInfectious DiseasesInfluenza VaccinesMedicineFemaleSeasonsResearch ArticleAdultmedicine.medical_specialtyAdolescentInfluenza vaccineClinical Research DesignScience030231 tropical medicinePopulationMicrobiologyHistory 21st CenturyInfectious Disease Epidemiology03 medical and health sciencesYoung AdultInternal medicineVirologyVaccine DevelopmentInfluenza Humanmedicinemedia_common.cataloged_instanceHumansEuropean UnionEuropean unioneducationBiologyAgedbusiness.industryInfluenza A Virus H3N2 SubtypeCase-control studyImmunityViral VaccinesInfluenzaSample size determinationCase-Control StudiesImmunologyClinical ImmunologybusinessPLoS ONE
researchProduct

The value of open-source clinical science in pandemic response

2021

International audience

Biomedical Research[SDV]Life Sciences [q-bio]Clinical scienceGlobal HealthCorrectionsMicrobiology1117 Public Health and Health Services1108 Medical MicrobiologyPandemicEconomicsHumansISARIC Clinical Characterisation GroupPandemicsCOVID-19/epidemiologyActuarial scienceInformation DisseminationSARS-CoV-2CommentISARICCOVID-191103 Clinical SciencesCommunicable Disease Control/methodsInfectious DiseasesOpen sourceCommunicable Disease ControlCOVID-19; Communicable Disease Control; Global Health; Humans; SARS-CoV-2; Biomedical Research; Information Dissemination; PandemicsValue (mathematics)HumanThe Lancet Infectious Diseases
researchProduct

ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19

2022

The International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) COVID-19 dataset is one of the largest international databases of prospectively collected clinical data on people hospitalized with COVID-19. This dataset was compiled during the COVID-19 pandemic by a network of hospitals that collect data using the ISARIC-World Health Organization Clinical Characterization Protocol and data tools. The database includes data from more than 705,000 patients, collected in more than 60 countries and 1,500 centres worldwide. Patient data are available from acute hospital admissions with COVID-19 and outpatient follow-ups. The data include signs and symptoms, pre-existing como…

EğitimSocial Sciences and HumanitiesInformation Security and ReliabilitySocial Sciences (SOC)Sosyal Bilimler ve Beşeri BilimlerEpidemiologyEDUCATION & EDUCATIONAL RESEARCHTemel Bilimler (SCI)BİLGİSAYAR BİLİMİ BİLGİ SİSTEMLERİMATHEMATICSSociology[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesProspective StudiesCOMPUTER SCIENCE INFORMATION SYSTEMSSTATISTICS & PROBABILITYMatematikBilgisayar Bilimi UygulamalarıComputer SciencesBilgi Güvenliği ve GüvenilirliğiEĞİTİM VE EĞİTİM ARAŞTIRMASIBİLGİ BİLİMİ VE KÜTÜPHANE BİLİMİBilgi sistemiComputer Science ApplicationsKütüphane ve Bilgi BilimleriHospitalizationNatural Sciences (SCI)Physical SciencesEngineering and TechnologySosyal Bilimler (SOC)Bilgisayar BilimiStatistics Probability and UncertaintyInformation SystemsHumanStatistics and ProbabilityHumans; Pandemics; Prospective Studies; SARS-CoV-2; COVID-19; HospitalizationSOCIAL SCIENCES GENERALLibrary and Information SciencesEducationSDG 3 - Good Health and Well-beingLibrary SciencesINFORMATION SCIENCE & LIBRARY SCIENCEİstatistik ve OlasılıkHumansSosyal ve Beşeri BilimlerBilgisayar BilimleriSocial Sciences & HumanitiesEngineering Computing & Technology (ENG)SosyolojiPandemicsPandemicSARS-CoV-2İSTATİSTİK & OLASILIKCOVID-19Mühendislik Bilişim ve Teknoloji (ENG)İstatistik Olasılık ve BelirsizlikSosyal Bilimler GenelCOMPUTER SCIENCEProspective StudieFizik BilimleriViral infectionMühendislik ve TeknolojiKütüphanecilik
researchProduct

Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults

2015

Objective: The prevalence of overweight and obesity is increasing among HIV-infected patients. Whether standard antiretroviral drug dosage is adequate in heavy individuals remains unresolved. We assessed the virological and immunological responses to initial efavirenz (EFV)-containing regimens in heavy compared to normal-weight HIV-infected patients. Design: Observational European cohort collaboration study. Methods: Eligible patients were antiretroviral-naive with documented weight prior to EFV start and follow-up viral loads after treatment initiation. Cox regression analyses evaluated the association between weight and time to first undetectable viral load ( 50 copies/ml) after initial s…

CyclopropanesMaleEfavirenz; HIV; Immunological response; Virological response; Weight; Adult; Antiretroviral Therapy Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections; Humans; Male; Middle Aged; Obesity; Regression Analysis; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load; Body WeightHIV InfectionsOverweight10234 Clinic for Infectious DiseasesCohort Studieschemistry.chemical_compoundAntiretroviral Therapy Highly ActiveImmunology and AllergyHIV InfectionImmunological responsevirus diseasesVirological responseMiddle AgedViral LoadReverse Transcriptase InhibitorTreatment OutcomeInfectious DiseasesAlkynesCohort2723 Immunology and AllergyRegression AnalysisReverse Transcriptase InhibitorsFemalemedicine.symptomViral loadCohort studyHumanBenzoxazineAdultmedicine.medical_specialtyEfavirenzImmunologyAntiretroviral Therapy610 Medicine & healthRegression AnalysiPharmacokineticsInternal medicinemedicineHumansHighly ActiveObesity2403 Immunologybusiness.industryProportional hazards modelBody WeightHIV2725 Infectious DiseasesEfavirenz; HIV; Immunological response; Virological response; Weight; Adult; Antiretroviral Therapy Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections; Humans; Male; Middle Aged; Obesity; Regression Analysis; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load; Body Weight; Immunology and Allergy; Immunology; Infectious Diseasesmedicine.diseaseWeightObesityBenzoxazinesCD4 Lymphocyte Countlnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]chemistryImmunologyCohort StudieEfavirenzbusiness
researchProduct

Respiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a …

2022

Invasive mechanical ventilation; COVID-19; Critical care Ventilación mecánica invasiva; COVID-19; Cuidado crítico Ventilació mecànica invasiva; COVID-19; Atenció crítica Background Up to 30% of hospitalised patients with COVID-19 require advanced respiratory support, including high-flow nasal cannulas (HFNC), non-invasive mechanical ventilation (NIV), or invasive mechanical ventilation (IMV). We aimed to describe the clinical characteristics, outcomes and risk factors for failing non-invasive respiratory support in patients treated with severe COVID-19 during the first two years of the pandemic in high-income countries (HICs) and low middle-income countries (LMICs). Methods This is a multin…

:enfermedades respiratorias::trastornos respiratorios::insuficiencia respiratoria [ENFERMEDADES]COVID-19; Critical care; High flow nasal cannula; Invasive mechanical ventilationRespiració artificialCritical Care and Intensive Care Medicine[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractCOVID-19 (Malaltia) - Tractament[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesCOVID-19; Critical care; High flow nasal cannula; Invasive mechanical ventilation; Humans; Prospective Studies; SARS-CoV-2; Tachypnea; COVID-19; Respiratory Insufficiency:virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES]HumansProspective StudiesInvasive mechanical ventilation:Otros calificadores::/terapia [Otros calificadores]TachypneaInsuficiència respiratòria - TractamentSARS-CoV-2:Therapeutics::Therapeutics::Respiratory Therapy::Respiration Artificial::Noninvasive Ventilation [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]COVID-19:Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES]:Other subheadings::/therapy [Other subheadings]:terapéutica::terapéutica::terapia respiratoria::respiración artificial::ventilación no invasiva [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]:Respiratory Tract Diseases::Respiration Disorders::Respiratory Insufficiency [DISEASES]High flow nasal cannulaProspective StudieCritical careRespiratory InsufficiencyHumanCritical Care
researchProduct

Association of country income level with the characteristics and outcomes of critically ill patients hospitalized with acute kidney injury and COVID-…

2023

Introduction Acute kidney injury (AKI) has been identified as one of the most common and significant problems in hospitalized patients with COVID-19. However, studies examining the relationship between COVID-19 and AKI in low- and low-middle income countries (LLMIC) are lacking. Given that AKI is known to carry a higher mortality rate in these countries, it is important to understand differences in this population. Methods This prospective, observational study examines the AKI incidence and characteristics of 32,210 patients with COVID-19 from 49 countries across all income levels who were admitted to an intensive care unit during their hospital stay. Results Among patients with COVID-19 ad…

acute kidney injurycovid-19NephrologyKidney International Reports
researchProduct